BG61215B1 - Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems - Google Patents

Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems Download PDF

Info

Publication number
BG61215B1
BG61215B1 BG96928A BG9692892A BG61215B1 BG 61215 B1 BG61215 B1 BG 61215B1 BG 96928 A BG96928 A BG 96928A BG 9692892 A BG9692892 A BG 9692892A BG 61215 B1 BG61215 B1 BG 61215B1
Authority
BG
Bulgaria
Prior art keywords
cell
vesicles
hemagglutinin
membrane
vesicle
Prior art date
Application number
BG96928A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG96928A (bg
Inventor
Reinhard Glueck
Peter Klein
Peter Hermann
Original Assignee
Nika Health Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nika Health Products Ltd filed Critical Nika Health Products Ltd
Publication of BG96928A publication Critical patent/BG96928A/bg
Publication of BG61215B1 publication Critical patent/BG61215B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Feedback Control In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Air Conditioning Control Device (AREA)
BG96928A 1991-02-02 1992-09-29 Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems BG61215B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91101414A EP0497997B1 (en) 1991-02-02 1991-02-02 Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems
PCT/EP1992/000089 WO1992013525A1 (en) 1991-02-02 1992-01-17 Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems

Publications (2)

Publication Number Publication Date
BG96928A BG96928A (bg) 1994-03-24
BG61215B1 true BG61215B1 (en) 1997-03-31

Family

ID=8206362

Family Applications (1)

Application Number Title Priority Date Filing Date
BG96928A BG61215B1 (en) 1991-02-02 1992-09-29 Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems

Country Status (22)

Country Link
US (1) US6040167A (sv)
EP (1) EP0497997B1 (sv)
JP (1) JP3404037B2 (sv)
KR (1) KR100205693B1 (sv)
AT (1) ATE125154T1 (sv)
AU (1) AU657730B2 (sv)
BG (1) BG61215B1 (sv)
BR (1) BR9204116A (sv)
CA (1) CA2079685C (sv)
DE (1) DE69111414T2 (sv)
DK (1) DK0497997T3 (sv)
ES (1) ES2077086T3 (sv)
FI (1) FI109969B (sv)
GE (1) GEP20002229B (sv)
GR (1) GR3017490T3 (sv)
HK (1) HK56696A (sv)
HU (1) HU215533B (sv)
NO (1) NO306194B1 (sv)
PL (2) PL296382A1 (sv)
RO (1) RO114736B1 (sv)
RU (1) RU2125868C1 (sv)
WO (1) WO1992013525A1 (sv)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5603872A (en) * 1991-02-14 1997-02-18 Baxter International Inc. Method of binding recognizing substances to liposomes
JP3407072B2 (ja) * 1991-02-14 2003-05-19 バクスター、インターナショナル、インコーポレイテッド リポソームへの認識物質の結合
US7097839B1 (en) * 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
ATE223701T1 (de) * 1994-05-31 2002-09-15 Inex Pharmaceutical Corp Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
AU6691496A (en) * 1995-08-01 1997-02-26 Advanced Therapies, Inc. Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
HUP9901790A3 (en) * 1996-05-08 2010-11-29 Nika Health Products Ltd Cationic virosomes as transfer system for genetic material
US7148324B1 (en) 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
CA2353816C (en) * 1998-12-14 2010-06-01 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class i restricted antigen presentation
JP2004513059A (ja) 1998-12-24 2004-04-30 ユセベ，ソシエテ　アノニム ペプチド産物、方法及び組成物
ATE258428T1 (de) * 1999-10-08 2004-02-15 Nika Health Products Ltd Kationische dosper virosomen
BR0016472A (pt) * 1999-12-17 2002-08-20 Cápsula de ignição indutivamente ativável para sistemas de retenção de ocupantes de assento
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
US20040176283A1 (en) * 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
DK1499294T3 (da) * 2002-04-29 2010-12-06 Biotesys Gmbh Polymeriserede, peptid-modificerede lipider som biologiske transportsystemer til mikronæringsstoffer
EP1447080A1 (en) * 2003-02-13 2004-08-18 Bestewil Holding B.V. Method for producing virosome-like particles
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
KR101376895B1 (ko) 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US20070160658A1 (en) * 2005-10-20 2007-07-12 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
JP5606067B2 (ja) 2006-09-15 2014-10-15 オタワ ホスピタル リサーチ インスティテュート 腫瘍崩壊性ラブドウイルス
CA3001467A1 (en) 2015-10-16 2017-04-20 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3173713D1 (en) * 1980-09-05 1986-03-20 Frappier Armand Inst Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4790987A (en) * 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
IL86650A0 (en) * 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
WO1991003258A1 (en) * 1989-09-01 1991-03-21 Board Of Regents, The University Of Texas System Immunoliposomes for transmittal of activating signals to cells
AU652778B2 (en) * 1990-10-15 1994-09-08 Quest International B.V. Treatment composition

Also Published As

Publication number Publication date
CA2079685C (en) 2001-11-27
NO923703D0 (no) 1992-09-24
ATE125154T1 (de) 1995-08-15
ES2077086T3 (es) 1995-11-16
HU9203141D0 (en) 1992-12-28
FI924418A0 (fi) 1992-10-01
DE69111414T2 (de) 1996-02-01
NO306194B1 (no) 1999-10-04
GR3017490T3 (en) 1995-12-31
RU2125868C1 (ru) 1999-02-10
DK0497997T3 (da) 1995-11-27
BR9204116A (pt) 1993-06-08
EP0497997B1 (en) 1995-07-19
AU1169392A (en) 1992-09-07
PL296382A1 (en) 1993-11-02
JP3404037B2 (ja) 2003-05-06
FI924418A (fi) 1993-04-03
NO923703L (no) 1992-11-26
US6040167A (en) 2000-03-21
PL170169B1 (en) 1996-10-31
RO114736B1 (ro) 1999-07-30
HUT66194A (en) 1994-10-28
HK56696A (en) 1996-04-12
HU215533B (hu) 1999-01-28
DE69111414D1 (de) 1995-08-24
FI109969B (sv) 2002-11-15
KR100205693B1 (en) 1999-07-01
WO1992013525A1 (en) 1992-08-20
AU657730B2 (en) 1995-03-23
BG96928A (bg) 1994-03-24
CA2079685A1 (en) 1992-08-03
EP0497997A1 (en) 1992-08-12
GEP20002229B (en) 2000-09-25
JPH05505406A (ja) 1993-08-12

Similar Documents

Publication Publication Date Title
BG61215B1 (en) Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems
JP6886406B2 (ja) コバルトポルフィリン・リン脂質コンジュゲート及びポリヒスチジンタグを含むナノ構造体
US20080268028A1 (en) Lyophilization of virosomes
AU4221489A (en) Affinity associated vaccine
US4148876A (en) Biological preparations
KR101290475B1 (ko) 인플루엔자 바이러스 및 비형 간염 바이러스로부터의항원을 포함하는 비로좀 입자
JPH10505320A (ja) 治療剤のビロゾーム媒介細胞内輸送
US11207421B2 (en) Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
CA3138856A1 (en) Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
HU219353B (en) Synthetic membrane vesicles as vehicles containing functionally active fusional peptides and pharmaceutical compositions comprising them
EP4108251A1 (en) Griffithsin for use in a method of preventing or treating infections with respiratory viruses
CA1334165C (en) Affinity associated vaccine
Mufeeda et al. International Journal of Modern Pharmaceutical Research
Rabinsky Effect of Protein Coatings on the Delivery Performance of Liposomes.